Could Judges Require Independent Experts To Explain Biosimilars?
Executive Summary
Biologics and biosimilars could cause courts to no longer blindly trust FDA’s scientific judgment, likely creating a whole new headache for the agency as companies go to court to challenge regulatory decisions.
You may also be interested in...
FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?
Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.
FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?
Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.
FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?
Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.